

Cover Story
Under ordinary circumstances, business arrangements built around the 340B drug discount program remain shrouded in secrecy.
In Brief
Clinical Roundup


Drugs & Targets
Trending Stories
- Jonathan Mahler on his front-page story in the NYT Magazine on Trump’s deliberate dismantling of America’s War on Cancer
- NCI releases names of members of ad hoc working group—filling the void left by BSA
- On Capitol Hill, NIH gets congressional support and RFK Jr. gets slammed
- NCI is “really, really sturdy” and won’t break, former directors Ned Sharpless and Kim Rathmell say at UNC Lineberger symposium
- ACOG says it will no longer accept federal funding
- Gonzalez-Angulo Found Guilty In MD Anderson Poisoning Case